Pharma Focus Asia

Bayer Announces Exclusive Licence Agreement with Cedilla Therapeutics

Thursday, June 01, 2023

Bayer and Cedilla Therapeutics have recently entered into an exclusive licence agreement to collaborate on the development and commercialisation of Cedilla Therapeutics' CyclinE1/CDK2 complex inhibitors.

As part of the agreement, Cedilla will receive an initial payment and may also be eligible for additional milestone payments linked to the progress of development and commercialisation efforts. In addition, Cedilla will receive royalties from any drugs derived from their technology that Bayer successfully brings to market.

Cyclin E, a binding partner of Cyclin Dependant Kinase 2 (CDK2), plays a crucial role in the development of certain cancers through overexpression or genetic activation. This unique approach allows for precise targeting of the cyclin E/CDK2 complex, specifically in a patient population with a high unmet medical need.

By selectively inhibiting this complex, Cedilla's small molecules have the potential to offer enhanced safety and efficacy compared to existing standard-of-care treatments. This innovative method of action holds promise for addressing the underlying oncogenic processes and improving outcomes for patients in need of more effective therapeutic options.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024